Donate

News

Categories
Sign up to our newsletter

General

Season’s Greetings
published December 17, 2017
THANK YOU for helping to make a difference  This year we achieved so much that would not have been possib
Read more
Jessy is beating his lymphoma
published April 18, 2017
New way of treating multiply relapsed DLBCL has worked wonders for young Jessy Carroll of Melbourne.  Rea
Read more
Cancer drug added to PBS list
published March 26, 2017
Rare cancer drug added to PBS Brentuximab vedotin (sold as Ad-ce-tr-is), was
Read more
Financial stress in cancer fight
published September 15, 2016
Australia ‘worst in world’ for financial stress in cancer fight Australians battling a common and deadl
Read more
Next PBAC Meeting
published September 13, 2016
Your chance to help The following treatments for lymphoma will be considered at the next Pharmaceutical Be
Read more
Strathfield Rotary Joined the Fight!
published August 26, 2015
We couldn't have asked for a more glorious evening in Sydney and we were immediately in awe of the stunnin
Read more
Titans Walk Tall for Lymphoma
published August 19, 2015
http://www.nrl.com/titans-walk-tall-for-cancer-cause/tabid/10874/newsid/89064/default.aspx
Read more
Ibrutinib in the Management of B-cell Malignancies
published May 23, 2015
Bruton’s tyrosine kinase (BTK) is a crucial component of the B-cell receptor-signaling pathway that has been
Read more
Potential for parenthood is good for adult female survivors of Hodgkin lymphoma
published May 18, 2015
A prospective, longitudinal study involving 590 female patients younger than 18 years at diagnosis who partici
Read more
Improving Outcomes in Mantle Cell Lymphoma
published May 17, 2015
 Approximately 6% of patients diagnosed with non-Hodgkin’s lymphoma have mantle cell lymphoma (MCL), wh
Read more
Radford Discusses Future of Novel Therapies in Non-Hodgkin Lymphoma
published May 17, 2015
Several novel agents, including idelalisib (Zydelig), belinostat (Beleodaq), and ibrutinib (Imbruvica), have s
Read more
Long-term strategy needed for those surviving cancer
published April 16, 2015
It was about 12 months after her treatment for ovarian cancer that Bec Secombe hit her lowest point.Secombe, w
Read more
Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Newsletter Sign Up

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.